---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-020282"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:47:25.993012+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BiomX to acquire Adaptive Phage Therapeutics; raises $50M in PIPE

## Summary
- BiomX to issue 9.16M common shares, 40,471 Series X Preferred (convertible into 1,000 common each), and 2.17M warrants at $5.00 to APT stockholders.
- Concurrent $50M private placement via 216,417 Series X Preferred shares and 108.2M warrants at $231.10 per unit; RBC and Laidlaw acted as placement agents.
- Merger expects to close on first business day after conditions met, no earlier than March 12, 2024; lock-up agreements with directors, officers, and major stockholders.
- Support agreements secured covering majority of voting stockholders to vote in favor of conversion and other proposals at special meeting.
- Registration rights agreement requires filing resale registration statement within 45 days of PIPE closing.

## SEC filing metadata
- accession: 0001213900-24-020282
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390024020282/0001213900-24-020282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390024020282/ea0201229-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-020282
- JSON: https://secwatch.observer/filing/0001213900-24-020282.json
- Plain text: https://secwatch.observer/filing/0001213900-24-020282.txt

## Key facts
- Material Agreements
  BiomX Inc. entered into Agreement and Plan of Merger with Adaptive Phage Therapeutics, Inc. (effective 2024-03-06).
  - Action: entry
  - Agreement: merger
  - Counterparty: Adaptive Phage Therapeutics, Inc.
  - Effective: 2024-03-06
  source text: On March 6, 2024, BiomX Inc., Inc., a Delaware corporation (the “Company” or “BiomX”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), BTX Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and Adaptive Phage Therapeutics, Inc., a Delaware corporation (“APT”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390024020282/0001213900-24-020282-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.